Takeda Pharmaceutical Company Limited

Takeda Chemical Industries, Inc.

Scohia Pharma, Inc.

Seiji Miwatashi

Shigenori Ohkawa

Yasufumi Miyamoto

Yasuhiro Hirata

Yuko Hitomi

Tomohiro Okawa

Koji Watanabe

Naoyuki Kanzaki

Hiroyuki Kimura

Nobuyuki Takakura

Hideki Furukawa

Jumpei Aida

Akito Shibuya

Naoyoshi Noguchi

Takeshi Yamasaki

Hideo Suzuki

Tsuyoshi Maekawa

Shizuo Kasai

Toshitake Kobayashi

Yayoi Nakayama

Kenichi Naruo

Satoshi Sasaki

Norihito Tokunaga

Kazuaki Takami

Shigemitsu Matsumoto

Tomohiro Kawamoto

Ken-ichi Naruo

Yayoi Yoshitomi

Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.

Aromatic compound

Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy. 

Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders

Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.

Aromatic compounds with GPR40 agonistic activity

Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.

Aromatic ring compound

(1) A 1,3-thiazole compound of which the 5-position is substituted with a 4-pyridyl group having a substituent including no aromatic group or (2) a 1,3-thiazole compound of which the 5-position is substituted with a pyridyl group having at the position adjacent to a nitrogen atom of the pyridyl group a substituent including no aromatic group has an excellent p38 MAP kinase inhibitory activity.

Substituted 1,3-thiazole compounds, their production and use

An optionally N-oxidized compound represented by the formula: wherein Rrepresents hydrogen, hydrocarbon, heterocycle, amino, acyl, Rrepresents an aromatic group, Rrepresents hydrogen, pyridyl, aromatic hydrocarbon, X represents oxygen, optionally oxidized sulfur, Y represents a bond, an oxygen, optionally oxidized sulfur, a group represented by the formula NR(Rrepresents hydrogen, hydrocarbon or acyl) and Z represents a bond or a divalent acyclic hydrocarbon, or a salt thereof has an excellent adenosine Areceptor antagonistic activity and is used as an agent for preventing or treating diseases related to an adenosine Areceptor. Furthermore, the compound (I) or a salt thereof has p38 MAP kinase inhibitory activity and TNF-&#x3b1; inhibitory activity and is used as an agent for preventing or treating diseases related to p38 MAP kinase and diseases related to TNF-&#x3b1;.

5-pyridyl-1,3-azole compounds, process for producing the same and use thereof

The present invention relates to a c-Jun N-terminal kinase inhibitor containing an azole compound (I) substituted by a nitrogen-containing aromatic group having substituent(s)(except a compound represented by the formula: ) or a salt thereof or a prodrug thereof.

JNK inhibitor

A 1,3-thiazole compound substituted at the 5-position by a pyridyl group optionally having substituent(s) has a superior p38 MAP kinase inhibitory activity and TNF-&#x3b1; production inhibitory activity.

Method for inhibiting p38 MAP kinase or TNF-&#x3b1; production using a 1,3-thiazole

Thiazolopyrimidine compounds, its production and use

Growing community of inventors

Ikeda, Japan

Seiji Miwatashi